Dr. Jack Cush reviews the news, regulatory and journal reports from the past week on RheumNow.com.
All News
Article
Article
Our immune system is armed with an array of defenses designed to detect and eliminate harmful threats. One of its most powerful defense mechanisms is the complement system—a group of proteins that patrols our body, ever vigilant for signs of infection or injury.
Article
Adalimumab is an effective treatment for JIA-associated uveitis and has been FDA approved for such use - but for how long and can the drug be withdrawn? An adalimumab (ADA) withdrawal trial has shown recurrence of uveitis, arthritis, or both, when the disease was previously controlled on ADA.
Article
A retrospective study of cutaneous lupus erythematosus (CLE) patients finds an increased risk of atherosclerotic cardiovascular disease (ASCVD) on par with systemic lupus patients.
Janet Pope
Tweet
1/3 of #axial #PsA
👇
No #SI joint changes , only #axial
@RheumNow #RNL2025
Catherine Blackwell
#ClinicalPearl https://t.co/YmoipL1bME
Eric Dein
Tweet
P2 Trial: DEU in PsA
Encouraging results for DCV 6 and 12 mg qd.
ACR20 63% for DCV 12 mg (p=0.0004)
Not yet FDA approved for PsA, only PsO
Pending P3
P2: DEU in SLE - PAISLEY
Improved SRI(4), CLASI-50 at w32
Merola
#RNL2025 @RheumNow https://t.co/RV7OPaZWjx
Richard Conway
Tweet
Combination therapy in PsA . Regulatory and reimbursement issues may inhibit such strategies (and potential adverse event concerns) but anecdotal evidence would suggest a role in difficult to treat cases. @RheumNow #RNL2025 https://t.co/IIoUiJyP95
Janet Pope
Tweet
#HOT #topic
Will #Rx of #PsO PREVENT onset of #PsA
Well, maybe 🤔
Alexis R Ogdie @RheumNow #RNL2025
70% of #psoriatic #arthritis is preceded by #psoriasis
Still a bit of a debate re prevention of PsA https://t.co/7bce8kcjdr
Richard Conway
Tweet
Risk factors for development of PsA in psoriasis. Psoriasis severity, obesity, and depression. @alexisogdie @RheumNow @RNL2025 https://t.co/obMDBvLLnx
Richard Conway
Tweet
Great graph from @AlexisOgdie on the effect of biologic treatment on PsA development in psoriasis. Obvious front-loading in those who need systemic therapy. But over time those who don't appear to develop more PsA @RheumNow @RNL2025 https://t.co/UxUZyKb0NA
Adela Castro
Tweet
Can treatment of PsO prevent PsA?
-Severity of PsO and obesity->Risk fx for PsA
-PRESTO scores: Predicts whether you will develop PsA in the next year vs next 5 years
-Does ttx of PsO impact development of PsA?
Trials are mostly observational (several confounders)
TriNetX data:… https://t.co/TBv3Y2TLZv https://t.co/1K0MtMQ5gn
Janet Pope
Tweet
Predicting #PsA
PRESTO study #obvious risks are #predictive
Alexis R Ogdie @RheumNow #RNL2025
bad PsO 2X ^PsA
High BMI
Depression
Modifiable risks #psoriasis #psoriatic #arthritis https://t.co/pOxidCWcg5
QD Clinic - New Palmoplantar Psoriasis and PsA
New Onset Palmoplantar PsO and PsA - what are the options?
Features Dr. Jack Cush.
QD Clinics - lessons from the clinic, sponsored by RNL2025 in Dallas, TX; Feb 8 & 9, 2025
Register at https://t.co/2dcFVgu8z6… https://t.co/3ubBL6HVGF https://t.co/Zdd6Dih5eZ
Is IL-23i better than IL-17i at lowering PsA risk? Retrospective, real-world EHR data study from TriNetX shows that among 4580 adult psoriasis pts (2,273 on IL23i vs 2,307 on IL17i), IL23i had signif lower PsA incidence (HR 0.60; 0.44–0.82, P 0.001), esp if 41-65 yrs (HR 0.42) &… https://t.co/ZuCAiOTIke https://t.co/8PkDCugYy0
QD Clinic - New Palmoplantar Psoriasis and PsA
New Onset Palmoplantar PsO and PsA - what are the options?
Features Dr. Jack Cush.
QD Clinics - lessons from the clinic, sponsored by RNL2025 in Dallas, TX; Feb 8 & 9, 2025
Register at https://t.co/2dcFVgu8z6… https://t.co/HZZuDvga58 https://t.co/wWKhnIECwB
Study of 702 pts who transitioned from PsO to PsA (median 9yrs) - no baseline differences in PsA pts who transitioned late (>9yrs); but on follow-up, the late group had lower Dz activity, less csDMARD use, but no difference in radiographic progression https://t.co/xUPXA79weS https://t.co/eUeemqovv8
Participation is Up! (1.31.2025)
Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow. We also have two call-in cases on "Ask Cush Anything".
https://t.co/kxMkDW5X8c https://t.co/AjIuNzk7co
NIH study of MSK disease burden finds research on neck pain as most underfunded (0.83%) followed by LBP (13.9%), OA (35.1%) & RA (66.3%) - NIAMS is low compared to other institutes. In USA, MSK dz affect 1 in 3 people, approximately 127.4 million individuals.… https://t.co/MqU9TsY6GR https://t.co/rRvUYc2yee
North American Real-world EHR data of PsA & axSpA pts (n 2200 Ea.) found no higher rates of CVD (acute MI, CVA or revascularization) or solid cancers (breast, colorectal, lung, prostate) when comparing JAKi to either TNFi or IL-17i use (over 3 years). https://t.co/macjpWxdnY https://t.co/9gXiomU3YD
Head-to-Head Clinical Trials
https://t.co/kLwVKRcnna https://t.co/XDhk9VAIin
